Menu Back toSession-3-GDPR-and-Data-Transparency-Requirements

Global Clinical Trials Transparency Conference

Session 3: GDPR and Data Transparency Requirements

Session Chair(s)

Merete  Joergensen, MBA, MSc

Merete Joergensen, MBA, MSc

  • Senior Trial Disclosure Director, Clinical Reporting Anchor & Disclosure
  • Novo Nordisk A/S, Denmark
How to ensure Data privacy and being Transparent at the same time gives rise to some considerations and concerns. What does this mean from a patient perspective, what are the considerations from industry trying to manoeuvre the requirements and what are the legal reality when working in this field.


David  Peloquin, JD

David Peloquin, JD

  • Senior Advisor, MRCT Center; Associate, Health care Group
  • Ropes & Gray LLP, United States
Deborah E. Collyar

Patient's perspectives on Data Privacy versus Data Transparency

Deborah E. Collyar

  • President
  • Patient Advocates In Research (PAIR), United States
Anne  Cutting

GDPR and Data Transparency: An Industry Perspective’

Anne Cutting

  • Director, Human Subject Research Governance
  • GSK, United Kingdom